Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

After holding leadership positions at contract manufacturers Patheon and Thermo Fisher Scientific, working in the food and ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk has received European approval to acquire Catalent, a U.S. drug manufacturer responsible for producing a large portion of Novo Nordisk’s popular obesity drug, Wegovy. However ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give Novo Nordisk control of manufacturing facilities currently operated by ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

2024 was quite a year for significant strategic action among the pharmaceutical giants. Here are five key trends that will ...

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

Novo's drug candidate, CagriSema, showed weight loss below expectations during a trial, dealing a blow to the company's plans ...